title: Venous thrombosis in patients with high-grade glioma.
abstract: OBJECTIVE
  High-grade glioma (HGG) patients are at particularly high risk of venous thromboembolism (VTE) occurrence and recurrence. VTE is associated with worsened survival in these patients. At present, the main challenge when prescribing anticoagulants in HGG patients is to address the risk of intracranial hemorrhage and provide the optimal treatment.
  
  
  RESULTS
  Here, we discuss the latest biological findings and their potential implications for better classification in daily practice and stratification of patients in future trials according to their risk of developing a VTE.
  
  
  CONCLUSIONS
  To help clinicians, international guidelines have been provided for cancer patients, but their implementation remains suboptimal. We report here the specificities of VTE management in HGG patients relative to other cancer patients. Particular aspects such as anticoagulation under targeted therapies, primary and secondary prophylaxis, and the role of new oral anticoagulants are discussed as well.
authors.affiliation: aNeurologie Department - Pitié-Salpétrière Hospital, Paris VI Pierre and Marie Curie University, Assistance Publique des Hôpitaux de Paris-Paris bNeuro-oncology Unit, Neurooncology Department, Nancy University Hospital, Central Hospital and CRAN UMR 7039 CNRS, SBS BEAM Department, Nancy University, Vandœuvre-lès-Nancy cNeuro-oncology Department, University Hospital dMedical Oncology Department, Oscar Lambret Center, Lille eINSERM U1192, PRISM Laboratory, Lille University, Villeneuve d'Ascq, Laboratoire PRISM, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Taillibert
authors.forename: Luc
authors.initials: L
authors.lastname: Taillandier
authors.forename: Emilie
authors.initials: E
authors.lastname: Le Rhun
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D001932:Brain Neoplasms / Q000150:complications* / Q000188:drug therapy; D005910:Glioma / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D015994:Incidence; D020300:Intracranial Hemorrhages / Q000139:chemically induced / Q000517:prevention & control; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; D000970:Antineoplastic Agents; D015415:Biomarkers